Arch Oncology is a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of best-in-class antibody therapies for the treatment of patients with cancer. Our next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class.
Our lead product candidate AO-176 is in a Phase 1 clinical trial for the treatment of patients with select solid tumors. In addition, we are advancing a number of pipeline programs, including anti-signal regulatory protein (SIRP) antibodies. Our leadership team has successfully developed new drugs for patients before and we are backed by leading investors, including RiverVest Venture Partners, Roche Venture Fund, 3×5 RiverVest Partners II-B, and Lightchain.